NCT04624178 - A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions

Leiomyosarcoma

Interventions

DRUG

Rucaparib

Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.

DRUG

Nivolumab

Nivolumab 480mg intravenously on day 1 of every four-week cycle.

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

Memorial Sloan Kettering Commack (Limited protocol activities), Commack

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale